Therefore, further studies are needed to address the issue whether PON1 reduction could be a pathogenic, contributory factor to increased risk of CAD in MS or that reduction would be simply the consequence of ancillary enzyme consumption/inactivation due to CAD/MS-associated oxidative stress. The gene discussed is PON1; the disease is myeloid sarcoma.